Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab
Gains Rights To Perjeta And Prolia/Xgeva Biosimilars As Well As Ipilimumab Option
Organon has agreed to pay an upfront price of $73m plus potentially a further $30m in milestone payments this year alone for the rights to Shanghai Henlius Biotech’s HLX14 denosumab and HLX11 pertuzumab biosimilar candidates outside China. The deal also offers Organon an option to negotiate with Henlius for rights to its ipilimumab biosimilar.
